Automata Funding, Investors & Competitors

Automata has raised $144M across 6 funding rounds, most recently a Series C in June 2026.

Last Automata funding round

Series C

Amount undisclosed · Jun 2026

Cumulative funding Automata raised

$144M

across 6 funding rounds

Key investors in Automata

  • Octopus Ventures
  • Hummingbird Ventures
  • ABB Ventures
  • LocalGlobe
  • Entrepreneurs First
  • Possible Ventures
  • HCVC
  • Aldea Ventures

Automata Overview

About Automata

Automata is a Rehovot, Israel-headquartered lab automation company serving life sciences research. Its robotic platforms, like the CellX platform, integrate pipetting, imaging, and AI analysis for high-throughput drug screening and genomics assays. Deployed in labs from Novartis and AstraZeneca, it accelerates experiment cycles by handling 24/7 operations.


Founded

2015

HQ

United KingdomLondon

Status

Privately held

Customer focus

B2B

Revenue model

Product sales

Automata Funding History

Automata has raised a total of $144M across 6 funding rounds.

Automata's first fundraising round was a $2M seed round in March 2016. The most recent completed round was a Series C in June 2026.

Automata funding rounds

Automata funding rounds
DateStageInvestorsRaisedDeal Summary
Jun 2026Series CEckuity (lead); Danaher--
Jan 2026Series CDanaher Ventures (lead); Dimension Capital (lead); Octopus Ventures; Entrepreneurs First; Tru Arrow Partners$45MAutomata, a London-based lab automation company, develops the LINQ platform, which integrates modular robotics with orchestration software to make wet labs programmable and AI-ready for life sciences applications in pharma, biotech, and research. On January 29, 2026, it closed a $45 million Series C funding round led by Dimension (referred to as Dimension Capital), with participation from Danaher Ventures, Tru Arrow Partners, Octopus Ventures, Entrepreneurs First, and others, plus a strategic investment partnership with Danaher Corporation. Murali Venkatesan Ph.D., Global Head of Danaher Ventures, joined the board. The funding will scale customer deployments globally, advance the data and closed-loop experimentation software for AI-driven drug discovery, and expand engineering, product, and customer success teams. Automata serves five top pharma companies, achieving growth through repeat deployments and major automation projects, delivering gains in experimental throughput, reproducibility, and efficiency. The Danaher partnership integrates technologies from Molecular Devices and Beckman Coulter Life Sciences with Automata’s software for enhanced liquid handling, genomic, and cell analysis workflows. This positions Automata in the competitive lab orchestration market, coordinating instruments, workflows, and AI data feeds, with Danaher providing distribution advantages though focused on its portfolio. The round follows prior funding, including a $40M Series B-II in October 2023 led by Dimension and others. Showcased at SLAS 2026 in Boston.
Oct 2023Undisclosed stageDimension Capital (lead); Octopus Ventures; Possible Ventures; Hummingbird Ventures; Isomer Capital; Aldea Ventures; A.P. Moller Holding$40MAutomata is a London-based company developing LINQ, a fully integrated, AI-ready lab automation platform that combines modular robotics, orchestration software, and unified data infrastructure to make physical labs programmable for life sciences, pharma, biotech, and research organizations. The platform reduces drug development timelines, costs, and error rates by enabling scalable, software-defined operations and closed-loop experimentation. In October 2023, Automata raised $40 million in a funding round backed by Dimension Capital and A.P. Moller Holding, with participation from Aldea Ventures, Hummingbird Ventures, Isomer Capital, Octopus Ventures, and Possible Ventures. Dimension Capital led the round. This followed a $50 million Series B in January 2022. Since the Series B, Automata reported 150% revenue growth and a 12-times increase in live system hours for customer-deployed systems. The funds support expansion of commercialization in life sciences, ongoing deployments, product development, and global growth, particularly in the US and Europe. A later $45 million Series C round was announced, led by Dimension with Danaher Ventures participation and a strategic partnership integrating Danaher's instruments like those from Molecular Devices and Beckman Coulter. Automata serves five top pharma companies with repeat deployments driving growth in experimental throughput, reproducibility, and efficiency. The company competes in the emerging lab orchestration market, positioning LINQ as the operating system between AI models and physical labs amid rising demand for AI-first biology infrastructure.
Feb 2022Series BABB Ventures (lead); Hummingbird Ventures (lead); Octopus Ventures (lead); Possible Ventures; Isomer Capital; HCVC; Blue Wire Capital; Aldea Ventures; IQT$50MAutomata Technologies is a UK-based company developing integrated lab automation platforms, including its LINQ system, to accelerate workflows in life sciences, drug discovery, diagnostics, and biotech for customers like NHS Trusts, The Francis Crick Institute, AstraZeneca, and bit.bio. The $50M Series B round on February 22, 2022, was led by Hummingbird Ventures, Octopus Ventures, and ABB Technology Ventures (ABB Ventures), with participation from Isomer Capital, Latitude Ventures, and others including Aldea Ventures, Blue Wire Capital, HCVC, IQT, and Possible Ventures. Proceeds funded expansion of Automata Labs in the UK and internationally, commercialization, deployment in Europe, UK, and US growth. This followed a $7.4M Series A in 2019 led by Hummingbird Ventures with ABB, Hardware Club, LocalGlobe, Firstminute Capital, and Entrepreneur First; subsequent rounds included $40M in October 2023 (Series B-II with Dimension, AP Moller, Aldea, Hummingbird, Isomer, Octopus, Possible, Unilabs) and $45M Series C in January 2026 (Tru Arrow, Octopus, Danaher, Entrepreneur First).
Mar 2019Series AHummingbird Ventures (lead); LocalGlobe; Firstminute Capital; HCVC; ABB Ventures; Entrepreneurs First$7M-
Mar 2016SeedABB Ventures (lead); LocalGlobe (lead)$2M-

Who has invested in Automata?

18 investors have backed Automata across its funding rounds, including Octopus Ventures, Hummingbird Ventures, ABB Ventures, LocalGlobe, Entrepreneurs First and Possible Ventures.

Lead investors include Eckuity, Danaher Ventures, Dimension Capital, ABB Ventures, Hummingbird Ventures and 2 other investors.


Automata Investors

Investors in Automata by funding rounds participated
InvestorHQRoundsRoleFirst check
Octopus VenturesUnited KingdomLondon3LeadFeb 2022
Hummingbird VenturesBelgiumBrussels3LeadMar 2019
ABB VenturesSwitzerlandSwitzerland3LeadMar 2016
Possible VenturesGermanyMunich2ParticipantFeb 2022
LocalGlobeUnited KingdomLondon2LeadMar 2016
Isomer CapitalUnited KingdomLondon2ParticipantFeb 2022
HCVCFranceParis2ParticipantMar 2019
Aldea VenturesSpainBarcelona2ParticipantFeb 2022
Entrepreneurs FirstUnited KingdomLondon2ParticipantMar 2019
Dimension CapitalUnited StatesNew York City, NY2LeadOct 2023
Firstminute CapitalUnited KingdomLondon1ParticipantMar 2019
Blue Wire CapitalUnited KingdomLondon1ParticipantFeb 2022
DanaherUnited StatesUnited States1ParticipantJun 2026

This data is available for Pro users. Sign up to see all 18 Automata investors.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

Automata Competitors

Automata competitors include listed companies like OMRON, ABB, Johnson Controls and Merck KGaA, and private ones like Medrobotics and Hadrian.

Public and private companies comparable to Automata
CompanyHQStatusRevenueEBITDAValuationRevenue Multiple
OMRONJapanJapanPublicly listed$4.9B$555M$7.7B1.6x
MedroboticsUnited StatesUnited StatesPrivate--$585M-
ABBSwitzerlandSwitzerlandPublicly listed$33B$6.9B$175B4.9x
Johnson ControlsUnited StatesUnited StatesPublicly listed$24B$3B$85B3.7x
Merck KGaAGermanyGermanyPublicly listed$24B$5.3B$66B3.1x
HadrianUnited StatesNew York City, NYPrivate--$7.9B-

Automata Public Comps

Automata is still privately-owned, but its public comps include Siemens, Schneider Electric, ABB, Hitachi, Mitsubishi, Delta Electronics (Thailand), Johnson Controls, Emerson Electric, Merck KGaA and Honeywell.

Last FYEV/RevenueEV/EBITDA
RevenueEBITDALast FYLTM2027ELast FYLTM2027E
Siemens$91B$15B3.0x2.9x18.1x15.7x
Schneider Electric$46B$9.5B4.3x3.9x21.0x18.4x
ABB$33B$6.9B5.4x4.9x25.9x22.6x
Hitachi$68B$11B2.2x2.2x13.8x13.5x
Mitsubishi$122B$8.7B1.2x1.2x17.2x21.8x
Delta Electronics (Thailand)$5.9B$1.1B15.0x11.4x80.8x64.9x
Johnson Controls$24B$3B4.0x3.7x31.0x20.0x
Emerson Electric$18B$4.7B5.2x5.0x19.9x17.1x

This data is available for Pro users. Sign up to see all Automata competitors and their valuation data.

Start Free Trial

Common questions about Automata

When was Automata founded?Automata was founded in 2015.
Where is Automata headquartered?Automata is headquartered in London, United Kingdom.
Is Automata publicly listed?No, Automata is a private, VC-backed company.
How much funding has Automata raised?Automata has raised $144M across 6 funding rounds.
What was Automata's last funding round?Automata's last funding round was a Series C in June 2026, led by Eckuity.
Who are Automata's investors?Automata's investors include Octopus Ventures, Hummingbird Ventures, ABB Ventures, Possible Ventures, LocalGlobe, Isomer Capital, HCVC, Aldea Ventures, Entrepreneurs First, Dimension Capital and 8 others.
Which companies are comparable to Automata?Companies comparable to Automata include OMRON, Medrobotics, ABB, Johnson Controls, Merck KGaA and Hadrian.

See companies similar to Automata

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial